CAS NO: | 2345755-20-4 |
包装 | 价格(元) |
1mg | 电议 |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
Cas No. | 2345755-20-4 |
Canonical SMILES | [Cl-][In+3]12([O-]C)([S]=C([N](C)C)[NH][N]1=CC3=CC=CC=[N]32)[Cl-] |
分子式 | C10H15Cl2InN4OS |
分子量 | 425 |
溶解度 | DMF: 10 mg/mL,DMF:PBS (pH 7.2) (1:2): 0.30 mg/mL,DMSO: 1 mg/mL,Ethanol: Slightly Soluble |
储存条件 | -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Indium (III) thiosemicarbazone 5b is an anticancer agent.1It is cytotoxic to A549, MCF-7 breast, MCF-7/DDP cisplatin-resistant breast, and Hl 7702 liver cancer cells (IC50s = 2.41, 1.97, 2.11, and 8.95 µM, respectively). Indium (III) thiosemicarbazone 5b decreases PI3K, Akt, mTOR, P-gp, and GSH levels in MCF-7/DDP cells.In vivo, indium (III) thiosemicarbazone 5b (2.5 µmol/kg) reduces tumor weight and volume in an MCF-7/DDP mouse xenograft model. Liposomes containing indium (III) thiosemicarbazone 5b also induce apoptosis and pro-death autophagy in MCF-7/DDP cells, as well as reduce tumor volume and weight in an MCF-7/DDP mouse xenograft model. 1.Jiang, M., Chu, Y., Yang, T., et al.Developing a novel indium(III) agent based on liposomes to overcome cisplatin-induced resistance in breast cancer by multitargeting the tumor microenvironment componentsJ. Med. Chem.64(19)14587-14602(2021) |